AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deSEP 232 min read$ZYME

Zymeworks Inc.: Zymeworks Completes Acquisition of Theravance Biopharma

Zymeworks Inc. (ZYME) completed its acquisition of Theravance Biopharma, integrating the company to diversify its revenue streams. Zymeworks will host a conference call on September 28 to discuss the transaction details. The acquisition aims to advance Zymeworks' strategy of combining innovative R&D with commercial and royalty-based cash flows.

Original reporting
finanznachrichten.de
Published Sep 23, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$ZYME
Bullish
high confidence
Mentioned
$ZYME · $TBPH
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$ZYMEBullishHigh
01

Why it matters

The deal removes acquisition uncertainty, potentially unlocking value for Zymeworks shareholders and setting a precedent for further consolidation in the biotech space.

02

Market read

Deal completion is a material corporate event for Zymeworks, likely influencing its stock price and sector dynamics.

03

What to watch

Potential regulatory approvals for Theravance assets and the financing terms of the acquisition.

Relevance 8/10Novelty 8/10Timing: Sept 23, 2026 (today)

Background

Zymeworks announced the completion of its previously disclosed acquisition of Theravance Biopharma, a move to broaden its therapeutic portfolio and royalty income.

Company-level read

Ticker impact

$ZYMEBullishHigh confidence
Context

Zymeworks Inc. completed its acquisition of Theravance Biopharma, finalizing the deal announced earlier.

Expected impact

Expect modest upside as investors price in the expanded asset base and synergies.

Evidence & confidence

Deal completion removes execution risk; the market typically rewards biotech firms that broaden revenue sources.

Market effects

Sector

Strengthens the biotech sector's M&A activity outlook, highlighting consolidation trends.

Regional

Positive for Canadian biotech market where Zymeworks is headquartered.

Global

Adds to global biotech M&A pipeline, may influence peer valuations.

Counterpoint

What could challenge this read

If integration challenges arise, the deal could dilute focus and strain cash, leading to downside.

Key entities

  • Company
    Zymeworks Inc.

    Biotech firm completing the acquisition.

  • Company
    Theravance Biopharma

    Target of the acquisition.

Read at source← All news

Related articles

SEP 23
$TBPHHigh

Theravance Biopharma, Inc. (TBPH): Completion of Acquisition or Disposition of Assets

Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of September 22, 2026 (this “ Agreement ”), is entered into by and between Zymeworks Inc., a Delaware corporation (“ Parent ”), and Computershare Inc., a Delaware corporation (“ Comput

SEC EDGAR 8-K2 min
SEP 23
$ZYMEHighAI 8/10

Zymeworks Inc. (ZYME): Completion of Acquisition or Disposition of Assets

Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Zymeworks Completes Acquisition of Theravance Biopharma • Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) Vancouver, British Columbia (September 23, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portf

SEC EDGAR 8-K2 min
SEP 8
$ZYMEMedAI 8/10

Zymeworks at Wells Fargo conference: cash flow, zanidatamab drive

Zymeworks (ZYME) presented at the Wells Fargo Healthcare Conference, highlighting its strategy focused on zanidatamab, royalty income, and acquisitions. Zanidatamab received FDA approval for gastric cancer, with Jazz Pharmaceuticals raising its peak sales estimate to $3B-$5B. Zymeworks raised $600M in debt, repurchased 10.5M shares, and plans to acquire Theravance Respiratory. Management expects profitability in 2026, with analysts forecasting 34% upside.

investing.com3 min
AUG 26
$ZYMEHighAI 9/10

FDA approves new indications for Ziihera

Zymeworks (ZYME) announced that its partner, Jazz Pharmaceuticals (JAZZ), received FDA approval for two Ziihera-containing regimens for treating HER2-positive gastroesophageal adenocarcinoma. This is the second FDA approval for zanidatamab in under two years, validating Zymeworks' Azymetric platform.

thepharmaletter.com2 min
AUG 26
$ZYMEHighAI 9/10

ZYME Looks 47.1% Overvalued on GF Value™

Zymeworks Inc (ZYME) shares rose 8% after FDA approval of Jazz Pharmaceuticals' Ziihera, triggering a $250M payment. ZYME's P/S ratio is 59.82x, higher than its historical median. Analysts set price targets at $55 and $40. The company's GF Score is 60, indicating moderate fundamental quality. Insiders sold $4.7M in shares over the past year.

gurufocus.com2 min
AUG 26
$ZYMEHighAI 9/10

H.C. Wainwright raises Zymeworks stock price target to $55 on FDA approval

H.C. Wainwright raised its price target on Zymeworks (ZYME) to $55 from $51, maintaining a Buy rating after FDA approval of Ziihera for HER2-positive gastroesophageal adenocarcinoma. The stock is up 85% over the past year. The approval triggers a $250 million payment from Jazz Pharmaceuticals (JAZZ). Analysts predict 188% revenue growth for FY2026. Zymeworks also announced an acquisition of Theravance Biopharma for $929 million.

investing.com2 min